The World Dermatological Market Outlook 2010-2024

The dermatological drug market continues to be important and competitive globally. New treatments for skin disorders and increasing disease prevalence will lead to further expansion of that market area, we predict. There are potential gains in all the main aspects of pharma development: novel drugs, drug delivery innovation, generics and biotechnology. Our brand new report - The World Dermatological Market Outlook 2010-2024 - explains why that market will expand, revealing where the most-exciting developments will lie during our forecast period. And how you can benefit from this expansion.

In particular, this study examines markets for treating the following skin disorders:
• Dermatitis
• Skin infections
• Acne
• Psoriasis.

Also covered are the following dermatological conditions:
• Alopecia
• Rosacea.

What types of therapeutic agent are likely to enter the market from 2010 onwards, and will they hold the potential to dominate this market area? Where will the best commercial opportunities in skin disorders lie from 2010 onwards? What are the most-crucial drivers and restraints in the global dermatological market? This report will provide you with the information that you need to understand current trends and future directions in pharmacological dermatology. In particular, we discuss commercial prospects for the following products in detail, from the present forward:

• Medrol
• Celestone
• Protopic
• Elocon
• Aldara
• Zovirax
• Lamisil
• Solodyn
• Differin
• BenzaClin
• Diane
• Daivobet
• Taclonex
• Dovonex
• Propecia
• Doryx
• Surgicel

Comprehensive analysis of the global dermatology market

The World Dermatological Market Outlook 2010-2024 critically examines that sector through a comprehensive review of primary and secondary information sources. Our new report provides detailed sales forecasts, market share analyses, discussions of pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 100 tables and figures included, as well as two full interviews with relevant experts. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.


Companies Listed

Abbott
Almirall
Altana
Anacor
AndroScience
Astellas
Astion
Barr
Bayer
Bayer Schering
Cephalon
CombinatoRx
Dr. Reddy's Laboratories
Ferrer
Galderma
Gene Signal International
GlaxoSmithKline
Graceway Pharmaceuticals
Gruenenthal
Impax Laboratories, Inc
Incyte
Intercytex
Johnson & Johnson
L'Oreal
Maruho
Medicis
Merck & Co.
Medivir
Minnesota 3M
Moberg Derma
Morria
Mylan Pharmaceuticals
Novartis
Nestle (Alcon, Galderma)
Otsuka
Pfizer
Pola Pharma
Sanofi-Aventis
Schering-Plough
Shionogi
Stiefel
Taisho
Teva
Toyama
Valeant
Warner Chilcott
XOMA
[Fade out the market survey infos]

Table of Contents
Chapter 1. Executive Summary
1.1 Dermatological Market Review
1.2 Aims, Scope and Format of the Report

Chapter 2. An Introduction to Dermatological Diseases and Treatments
2.1 An Introduction to Dermatology
2.1.1 The Structure of the Skin
2.1.2 Hair
2.1.3 Nails
2.1.4 Sweat and Serbacous Glands
2.2.1 Protection
2.2.2 Sensation
2.2.3 Vitamin D Synthesis
2.2.4 Temperature Regulation and Heat Insulation
2.2.5 Storage
2.2.6 Prevention of Water Loss
2.3 Common Skin Diseases
2.4 An Introduction to Acne Vulgaris
2.4.1 Acne Conglobata
2.4.2 Acne Fulminans
2.4.3 Gram-Negative Folliculitis
2.4.4 Pyoderma Faciale
2.4.5 Causes of Acne
2.5 An Introduction to Dermatitis
2.5.1 Atopic Dermatitis
2.5.2 Contact Dermatitis
2.5.3 Seborrheic Dermatitis
2.5.4 Nummular Dermatitis
2.5.5 Perioral Dermatitis
2.6 An Introduction to Psoriasis
2.6.1 Plaque Psoriasis
2.6.2 Guttate Psoriasis
2.6.3 Pustular Psoriasis
2.6.4 Inverse Psoriasis
2.6.5 Erythrodermic Psoriasis
2.7 An Introduction to Rosacea
2.7.1 Erythematotelangiectatic Rosacea
2.7.2 Papulopustular Rosacea
2.7.3 Phymatous Rosacea
2.7.4 Ocular Rosacea
2.8 An Introduction to Alopecia
2.8.1 Alopecia Areata
2.8.2 Alopecia Totalis
2.8.3 Alopecia Universalis
2.8.4 Androgenetic Alopecia
2.8.5 Alopecia Barbae
2.8.6 Alopecia Mucinosa
2.8.7 Traction Alopecia
2.8.8 Anagen Effluvium
2.8.9 Telogen Effluvium
2.9 An Introduction to Infectious Diseases of the Skin
2.9.1 Bacterial Skin Infections
2.9.1.1 Impetigo
2.9.1.2 Folliculitis
2.9.1.3 Cellulitis
2.9.1.4 Furunculosis
2.9.1.5 Carbuncle
2.9.2 Fungal Skin Infections
2.9.2.1 Tinea Pedis (Athlete's Foot)
2.9.2.2 Tinea Unguium (Ringworm of the Nails)
2.9.2.3 Tinea Corporis (Ringworm of the skin)
2.9.2.4 Tinea Capitis (Scalp Ringworm)
2.9.2.5 Kerions
2.9.3 Viral Skin Infections
2.9.3.1 Molluscum Contagiosum
2.9.3.2 Warts
2.9.3.3 Herpes Simplex
2.9.3.4 Chickenpox
2.9.3.5 Herpes Zoster
2.10 Common Skin Treatments
2.10.1 Creams and Semisolid Emulsions
2.10.2 Ointments
2.10.3 Lotions
2.10.4 Solutions
2.10.5 Occlusive Therapy
2.10.6 Cleansing Agents
2.10.7 Protecting Powders and Hydrophilic Polymer
2.10.8 Anti-Infective Agents
2.10.9 Anti-Inflammatory Agents

Chapter 3. The World Dermatological Market, 2010-2024
3.1 The World Dermatological Market in 2009
3.2 The World Dermatological Market Forecast, 2010-2024
3.3 The Dermatitis Market Dominates the World Dermatological Market
3.4 The Psoriasis Market Will Show the Highest Increase in Market Share
3.5 Solodny is the Leading Drug in the Dermatological Market in 2009
3.6 Dermatological Blockbuster Drugs Will Be Increasingly Rare.
3.7 The Future of the Dermatology Market
3.8 The World Dermatology Market - Overview

Chapter 4. The World Dermatitis Market, 2010-2024
4.1 The World Dermatitis Market in 2009
4.2 The World Dermatitis Market Analysis 2010-2024
4.3 Medrol (Methylprednisolone Acetate)
4.3.1 Medrol Currently Leads the Dermatitis Market
4.3.2 Will Medrol Lead the Dermatitis Market in 2024?
4.4 Celestone (Betamethasone)
4.4.1 Analysis of Forecast Celestone Sales 2009-2024
4.5 Protopic (Tacrolimus)
4.5.1 Protopic Will Show an Early Increase in Revenues - But Will It Last?
4.6 Elocon (Mometasone Fuorate)
4.6.1 Elocon Suffers From Generic Competition
4.7 The World Dermatitis Market - Summary

Chapter 5. The World Infectious Skin Diseases Market, 2010-2024
5.1 The World Infectious Skin Diseases Market in 2009
5.1.1 Topical Viral Infection Products Lead the Market in 2009
5.1.2 In 2009, Dermatological Antifungal Products Account for Half of Sales
5.2 The World Infectious Skin Disease Market Forecast, 2010-2024
5.3 Aldara (Imiquimod)
5.3.1 Aldara Leads the Infectious Skin Disease Market in 2009
5.3.2 Aldara Will Show An Early Increase in Revenues - But Will It Last?
5.4 Zovirax (Aciclovir)
5.4.1 Analysis of Forecast Zovirax Sales 2009-2024
5.5 Lamisil (Terbinafine)
5.5.1 Lamisil is the Leading Dermatological Antifungal Treatment in 2009
5.6 The World Infectious Skin Diseases Market - Summary

Chapter 6. The World Acne Market, 2010 - 2024
6.1 The World Acne Market in 2009
6.1.1 Products Leading the Acne Market, 2009
6.2 The World Acne Market Forecast 2010-2024
6.3 Solodyn (Minocycline)
6.3.1 Solodyn Currently Leads the World Acne Market
6.3.2 Will Solodyn Sales Continue to Grow?
6.4 Differin (Adapalene)
6.4.1 Sales Forecast for Differin, 2009-2024
6.4.2 Differin - Life Cycle Management
6.5 BenzaClin (Benzoyl peroxide and Clindamycin)
6.5.1 BenzaClin Sales Forecast Analysis 2009-2024
6.6 Diane
6.6.1 Sales Forecast for Diane, 2009-2024
6.7 The World Acne Market - Summary

Chapter 7. The World Psoriasis Market, 2010-2024
7.1 The World Psoriasis Market in 2009
7.1.1 Topical Antipsoriasis Treatments Lead the Psoriasis Market in 2009
7.2 The World Psoriasis Market Forecast 2010-2024
7.3 Daivobet (Calcipotriol & Betamethasone)
7.3.1 Daivobet Leads the Psoriasis Market in 2009
7.3.2 Daivobet Will Benefit from the Removal of Raptiva from the Market
7.4 Taclonex (Calcipotriol & Betamethasone)
7.4.1 Sales Forecast for Taclonex, 2009-2024
7.5 Dovonex (Calcipotriol)
7.5.1 Analysis of Dovonex Sales Forecast, 2009-2024
7.6 The World Psoriasis Market - Summary

Chapter 8. The World Market for Miscellaneous Dermatological Drugs, 2010-2024
8.1 The Miscelleaneous Dermatological Drug Market in 2009
8.2 The Miscelleaneous Dermatological Drug Market Analysis, 2010-2024
8.3 Propecia (Finasteride)
8.3.1 Revenues of Propecia Will Fall, 2009-2024
8.3.2 Other Alopecia Products
8.4 Doryx (Doxycycline Hyclate)
8.4.1 Forecast Sales of Doryx, 2009-2024
8.5 Surgicel
8.5.1 Forecast Sales of Surgicel, 2009-2024
8.6 The Miscellaneous Market - Summary

Chapter 9. Issues Affecting the Market for Dermatological Pharmaceuticals
9.1 SWOT Analysis of the World Dermatological Market
9.2 Market Drivers
9.3 Market Restraints
9.4 There is Scope for Expansion into Related Markets
9.5 Advances in Technology are Likely to Bring Benefits to the Market
9.6 Consumer Bargaining Power
9.7 Competition in the Dermatological Market Will Become Increasingly Intense
9.8 Substitutes
9.9 A Discussion of Generic Drugs in This Market - How Great is Their Threat?

Chapter 10. Dermatological Country Markets
10.1 The Dermatological Market - Regional Breakdown
10.2 Countries Leading the Dermatological Market, 2008
10.3 The Dermatological Market in the Nine Major Country Markets
10.3.1 The Dermatological Market in the US
10.3.2 The Dermatological Market in Japan
10.3.3 The Dermatological Market in Germany
10.3.4 The Dermatological Market in France
10.3.5 The Dermatological Market in the UK
10.3.6 The Dermatological Market in Italy
10.3.7 The Dermatological Market in Spain
10.3.8 The Dermatological Market in India
10.3.9 The Dermatological Market in China

Chapter 11. The Dermatological Pharmaceutical Pipeline
11.1 The Potential of the Dermatological Market Has Encouraged R&D
11.2 New Technology in Pipeline Developments
11.2.1 Reformulation
11.2.2 Combination Treatments
11.2.3 New mechanisms
11.2.4 Drug Delivery Technology
11.3 Potential Entrants
11.4 Pipeline Products in the Dermatitis Sector
11.5 Pipeline Products in the Infectious Skin Disease Sector
11.6 Pipeline Products in the Acne Sector
11.7 Pipeline Products in the Psoriasis Sector
11.8 Pipeline Products for Miscellaneous Dermatologicals
11.9 Innovation Rules for Early-Stage PipelineDrugs

Chapter 12. Expert Views from Key Opinion Leaders
12.1 Interview with the Product Development Director of a Pharmaceutical Company
12.1.1 The Future of the Dermatology Market
12.1.2 Areas Offering Growth Opportunities
12.1.3 Future Development Trend
12.1.4 Pipeline Products
12.1.5 Unmet Needs in Dermatology
12.1.6 Threats Facing the Dermatology Market
12.2 Interview With Dr M.J.Thornton, BSc, PhD, Cutaneous Biology Group, University of Bradford.
12.2.1 Androgen Based Science and Dermatology
12.2.2 Key Areas For Dermatological Research
12.2.3 Unmet Needs in Dermatology
12.2.4 Future Developments
12.2.5 Challenges in Dermatology

Chapter 13. Conclusions
13.1 The World Dermatological Market Will Experience Gradual Financial Growth
13.2 Market Drivers in the Dermatological Market
13.3 Market Restraints in the Dermatological Market
13.4 Will The Dermatitis Market Continue to Dominate the Dermatology Market?
13.5 The Skin Infection Market Faces Strong Generic Competition - Can it Expand?
13.6 Will the Acne Market Share Increase or Decline?
13.7 Will Growth of the Psoriasis Market Slow Down?
13.8 Why Growth in the Overall World Dermatological Market Will Continue
[Fade out table of contents]

Table 3.1 The World Dermatological Market Forecast, 2009-2016
Table 3.2 The World Dermatological Market Forecast, 2017-2024
Table 3.3 Leading Dermatological Markets Forecast, 2009-2016
Table 3.4 Leading Dermatological Markets Forecast, 2017-2024
Table 3.5 Market Shares of The Leading Dermatological Markets (%)
Table 3.6 The Leading Drugs in the World Dermatological Market
Table 3.7 Leading Companies in the Dermatological Market
Table 4.1 Total Dermatitis Market Forecast, 2009-2016
Table 4.2 Total Dermatitis Market Forecast, 2017-2024
Table 4.3 The World Dermatitis Market Drugs Forecast, 2009-2016
Table 4.4 The World Dermatitis Market Drugs Forecast, 2017-2024
Table 4.5 Market Share of the Leading Dermatitis Drugs (%)
Table 4.6 Leading Dermatitis Products Rank Comparison, 2009 and 2024
Table 5.1 Total Infectious Skin Diseases Market Forecast, 2009-2016
Table 5.2 Total Infectious Skin Diseases Market Forecast, 2017-2024
Table 5.3 Sales of Skin Infection Products by Class (%), 2009
Table 5.4 The World Infectious Skin Disease Market Drug Forecast, 2009-2016
Table 5.5 The World Infectious Skin Disease Market Drug Forecast, 2017-2024
Table 5.6 Market Share of the Leading Skin Infection Drugs (%)
Table 5.7 Leading Skin Infection Products Rank Comparison, 2009 and 2024
Table 6.1 Total Acne Market Forecast, 2009-2016
Table 6.2 Total Acne Market Forecast, 2017-2024
Table 6.3 The World Acne Market Drugs Forecast, 2009-2016
Table 6.4 The World Acne Market Drugs Forecast, 2017-2024
Table 6.5 Market Share of the Leading Acne Drugs (%)
Table 6.6 Leading Acne Products Rank Comparison, 2009 and 2024
Table 7.1 Total Psoriasis Market Forecast, 2009-2016
Table 7.2 Total Psoriasis Market Forecast, 2017-2024
Table 7.3 The World Psoriasis Market Drugs Forecast, 2009-2016
Table 7.4 The World Psoriasis Market Drugs Forecast, 2017-2024
Table 7.5 Market Share of the Leading Psoriasis Drugs (%)
Table 7.6 Leading Psoriasis Products Rank Comparison, 2009 and 2024
Table 8.1 Forecast of the Miscelleanous Market, 2009-2016
Table 8.2 Forecast of the Miscelleanous Market, 2017-2024
Table 8.3 World Market Forecast for Miscellaneous Dermatologicals ($m), 2008-2016
Table 8.4 World Market Forecast for Miscellaneous Dermatologicals ($m), 2017-2024
Table 8.5 Market Share of the Leading Miscellaneous Drugs (%)
Table 8.6 Leading Miscellanous Products Rank Comparison, 2009 and 2024
Table 9.1 SWOT Analysis of the World Dermatological Market
Table 10.1 The Dermatological Market Revenues by Region ($m), 2008
Table 10.2 Countries Leading the Dermatological Market, 2008
Table 10.3 Dermatological Market Forecast for the Nine Major Country Markets, 2008-2016
Table 10.4 Dermatological Market Forecast for the Nine Major Country Markets, 2017-2024
Table 10.5 The Nine Major Country Markets - Market Share (%), 2009, 2014 & 2024
Table 11.1 Key Pipeline Products for the Treatment of Dermatitis
Table 11.2 Key Pipeline Products for the Treatment of Infectious Skin Diseases
Table 11.3 Key Pipeline Products for the Treatment of Acne
Table 11.4 Key Pipeline Products for the Treatment of Psoriasis
Table 11.5 Key Pipeline Miscellaneous Dermatologicals

Figure 3.1 World Dermatological Market Forecast ($m), 2009 - 2024
Figure 3.2 The Leading Dermatological Markets Revenues ($m) 2009- 2024
Figure 3.3 Market Share of the Leading dermatological Markets (%), 2009-2024
Figure 3.4 The Leading Drugs in the World Dermatological Market, 2009
Figure 4.1 World Dermatitis Market Sales ($m), 2009-2024
Figure 4.2 Leading Dermatitis Drugs Forecast ($m), 2009-2024
Figure 4.3 Market Share (%) of the Leading Dermatitis Products, 2009
Figure 4.4 Market Share (%) of the Leading Dermatitis Products, 2014
Figure 4.5 Market Share (%) of the Leading Dermatitis Products, 2024
Figure 4.6 Medrol Sales Forecasts ($m), 2009-2024
Figure 4.7 Celestone Sales Forecast ($m)
Figure 4.8 Protopic Sales Forecast ($m), 2009-2024
Figure 4.9 Elocon Sales Forecast ($m), 2009-2024
Figure 5.1 World Infectious Skin Disease Market Revenues ($m), 2008- 2024
Figure 5.2 Leading Infectious Skin Disease Drugs Forecast ($m), 2009- 2024
Figure 5.3 Market Share (%) of the Leading Skin Infection Products, 2009
Figure 5.4 Market Share (%) of the Leading Skin Infection Products, 2014
Figure 5.5 Market Share (%) of the Leading Skin Infection Products, 2024
Figure 5.6 Aldara Sales Forecasts ($m), 2009-2024
Figure 5.7 Zovirax Sales Forecasts ($m), 2009-2024
Figure 5.8 Lamisil Sales Forecasts ($m), 2009-2024
Figure 6.1 World Acne Market Sales ($m), 2008-2024
Figure 6.2 Leading Acne Drugs Forecast ($m), 2009-2024
Figure 6.3 Market Share (%) of the Leading Acne Products, 2009
Figure 6.4 Market Share (%) of the Leading Acne Products, 2014
Figure 6.5 Market Share (%) of the Leading Acne Products, 2024
Figure 6.6 Solodyn Sales Forecast ($m), 2009-2024
Figure 6.7 Differin Sales Forecasts ($m), 2009-2024
Figure 6.8 BenzaClin Sales Forecasts ($m), 2009-2024
Figure 6.9 Diane Sales Forecasts ($m), 2009-2024
Figure 7.1 World Psoriasis Market Sales ($m), 2009-2024
Figure 7.2 Leading Psoriasis Drugs Forecast ($m), 2009-2024
Figure 7.3 Market Share (%) of the Leading Psoriasis Products, 2009
Figure 7.4 Market Share (%) of the Leading Psoriasis Products, 2014
Figure 7.5 Market Share (%) of the Leading Psoriasis Products, 2024
Figure 7.6 Daivobet Sales Forecasts ($m), 2009-2024
Figure 7.7 Taclonex Sales Forecast ($m), 2009-2024
Figure 7.8 Dovonex RSales Forecast ($m), 2009-2024
Figure 8.1 World Market Forecast for Miscellaneous Dermatologicals ($m), 2009-2024
Figure 8.2 Forecast for Leading Drugs in the Miscellaneous Dermatologicals Market ($m), 2009 -2024
Figure 8.3 Market Share (%) of Leading Drugs in the Miscellaneous Dermatologicals Market, 2009
Figure 8.4 Market Share (%) of Leading Drugs in the Miscellaneous Dermatologicals Market, 2014
Figure 8.5 Market Share (%) of Leading Drugs in the Miscellaneous Dermatologicals Market, 2024
Figure 8.6 Propecia Sales Forecast ($m) 2009-2024
Figure 8.7 Doryx Sales Forecast ($m) 2009-2024
Figure 8.8 Surgicel Sales Forecast ($m) 2009-2024
Figure 10.1 Dermatological Market Revenues ($m) and Share (%) by Region
Figure 10.2 The 10 Countries Leading the Dermatological Market in 2008 - Revenues ($m)
Figure 10.3 US and Japan Dermatological Market Forecasts, 2009-2024
Figure 10.4 European, Indian and Chinese Dermatological Market Forecasts, 2009-2024
Figure 10.5 Dermatological Market Share (%) by Country, 2009
Figure 10.6 Dermatological Market Share (%) by Country, 2014
Figure 10.7 Dermatological Market Share (%) by Country, 2024
[Fade out list of tables / figures]